The combination of enzalutamide with androgen deprivation therapy (ADT) significantly increases the chance of five-year ...

Discover a study that also highlighted that treatment intensification with enzalutamide benefited patients regardless of ...

An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib ...

Pfizer Inc. (NYSE:PFE) has unveiled major advances in cancer research at the 2025 ASCO Annual Meeting, spotlighting robust ...

Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, ...

Five- and eight-year trial data to be presented at ASCO demonstrate durable survival outcomes with Xtandi (enzalutamide) plus ...

Ed Burgess, diagnosed with stage IV prostate cancer, shares his journey of survival thanks to a combination of hormone therapy and the drug enzalutamide, highlighting the personal impact of research ...

The FDA's ODAC voted unanimously against the risk-benefit profile of talazoparib and enzalutamide for the treatment of mCRPC ...

Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 ...

The new therapy combines two existing cancer drugs, enzalutamide and talazoparib. Enzalutamide, known by its brand name XTANDI, has been used as a treatment for metastatic castration-resistant ...

OMAHA-003: A phase 3 study of CYP11A1 inhibitor opevesostat versus next-generation hormonal agent (NHA) switch in metastatic castration-resistant prostate cancer (mCRPC) after NHA and taxane-based ...

Astellas & Pfizer’s Xtandi shows long-term overall survival in metastatic hormone-sensitive prostate cancer: Tokyo Saturday, May 24, 2025, 13:00 Hrs [IST] Astellas Pharma Inc. a ...